

## Sécuril® Propio-Fidus®

Sécuril® is a novel formulation designed to naturally support intestinal health.\* It contains a special type of probiotic bacteria found in food called *Propionibacterium freudenreichii* (PF), which can simultaneously function as a prebiotic.

Propionic bacteria have been used for centuries to make Swiss and Emmental cheeses. Sécuril® supplies two researched strains of PF that are bile and gastric acid resistant, and that offer optimal benefits for gut health.\* These propionic bacteria can reproduce in the lower gut and generate prophylactic short-chain fatty acids (SCFA), including propionate and acetate.\* These SCFA lower the pH, protect the intestinal lining, down-regulate NF-KB (nuclear factor-kappa B), and support absorption of calcium, magnesium and potassium.\*



#76220 30 capsules

## **Key Features**

- Produces protective short chain fatty acids in the intestinal tract\*
- Enhances the growth of the body's own bifidus bacteria\*
- Promotes normal bowel transit times\*
- Helps balance and normalize overall bowel function\*





Propionic acid can also serve as food for the body's native bifidobacteria. As such, Sécuril® is a prebiotic, helping to promote growth and maintain levels of the body's own healthy bacteria.\* The average human intestinal tract has about 100 trillion bacteria, and of its two primary types of friendly bacteria, bifidobacteria and lactobacilli, the bifidobacteria are dominant, outnumbering lactobacilli approximately 1000:1. Healthy amounts of bifidobacteria help restrict the development of putrefying bacteria and decrease the formation of undesirable compounds such as phenols, ammonia, and biogenic amines.\* Bifidobacteria can also stimulate the intestinal immune defense system, increasing IgA.\* There are five common strains of bifidobacteria: B. infantis, B. adolescentis, B. bifidum, B. longum, and B. breve. Sécuril® provides the nutrition that promotes growth of all these bifidobacteria, helping the body optimize its own unique, health-promoting blend of the different stains.\*

Studies show that the bacteria in Sécuril® survive and reproduce in the human gut, and that they significantly increase the levels of bifidobacteria and SCFA.\* PF produces a bifidogenic growth stimulator called 1,4-dihydroxy-2-napthoic acid (DHNA), which stimulates bifidus growth even at a very low concentration, and may inhibit undesirable bacteria.\* DHNA tolerates proteolytic enzymes and heat, allowing it to reach the large intestine where bifidobacteria mostly reside. Animal studies show that DHNA protects gut mucosa from inflammation, normalizes butyrate levels and helps restore healthy flora.\* Human research confirms that Sécuril® can increase healthy bifido flora in a matter of weeks, and thereby help normalize intestinal motility and transit time, and control putrefaction.\*

The freeze-dried bacteria in Sécuril® are not heat sensitive, and the product does not require refrigeration. Because Sécuril® is sensitive to humidity, each capsule is sealed within a plastic compartment, and each sheath of capsules is sealed in a pouch with a desiccant. For best results, once the sheath is removed from the pouch, the capsules should be consumed within two weeks.

Sécuril® contains no wheat, corn, soy, gluten, yeast, dairy, eggs or other common allergens. At the time of manufacture, each capsule contains 7.5 billion bacteria, in order to insure full label potency through date of expiration. Each capsule contains 260 mg of FOS. Sécuril® is produced by Compagnie Générale de Diététique - Laboratoire Yalacta, in France, and meets all European Union food supplement requirements for safety, purity, and potency. Strains are selected and deposited at the CNCM of the Pasteur Institute, titrating 5 billion bacteria per capsule. Sécuril® may be used by individuals of any age.

## Supplement Facts

Serving Size Servings Per Container 2 capsules 15

\*Daily Value not established

Other ingredients: Hydroxypropyl methylcellulose, gellan gum, FOS (from beet).

**Suggested Use:** As a dietary supplement, 1 or 2 capsules with water in the morning, or as directed by a healthcare practitioner.

Do not exceed the recommended dose. Not to be used as a substitute for a varied diet.

## References

Langsrud T and Reinbold GW. Flavor development and microbiology of Swiss cheese- A review. III. Ripening and flavor production. J. Milk Food Technol. 1973; 36:593-609.

Kaneko T, Mori H, Iwata M, and Meguro S. Growth stimulator for Bifidobacteria produced by Propionibacteria freudenreichii and several intestinal bacteria. J Dairy Sci. 1994; 77:393-404.

Zárate G, González S, Chaia AP. Assessing survival of dairy propionibacteria in gastrointestinal conditions and adherence to intestinal epithelia. Methods Mol Biol. 2004;268:423-32.

Zárate G, Morata De Ambrosini V, Perez Chaia A, González S. Some factors affecting the adherence of probiotic Propionibacterium acidipropionici CRL 1198 to intestinal epithelial cells. Can J Microbiol. 2002 May;48(5):449-57. Zárate G, Morata de Ambrosini VI, Chaia AP, González SN. Adhesion of dairy propionibacteria to intestinal epithelial tissue

Zárate G, Chaia AP, González S, Oliver G. Viability and beta-galactosidase activity of dairy propionibacteria subjected to digestion by artificial gastric and intestinal fluids. I Food Prot

2000 Sep;63(9):1214-21.

Lan A, Bruneau A, Philippe C, Rochet V, Rouault A, Hervé C, Roland N, Rabot S, Jan G. Survival and metabolic activity of selected strains of Propionibacterium freudenreichi in the gastrointestinal tract of human microbiota-associated rats. Br J Nutr. 2007 Apr;97(4):714-24.

Lan A, Bruneau A, Bensaada M, Philippe C, Bellaud P, Rabot S, Jan G. Increased induction of apoptosis by Propionibacterium freudenreichii TL133 in colonic mucosal crypts of human microbiota-associated rats treated with 1,2-dimethylhydrazine. Br J Nutr. 2008 May 9:1-9.

Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis. 2007 Mar;12(3):573-91.